



# Independent Medical Education Request for Proposals

Improving Shared Decision Making in Hemophilia: Visiting Professorship Program

## **Summary of Opportunity**

#### Overview

Pfizer and the Hemostasis & Thrombosis Research Society (HTRS) are offering a new Independent Medical Education grant opportunity supporting Visiting Professorships for organizations with identified needs for hemophilia-focused education.

Clinicians, physician-scientists, and multidisciplinary care teams at recipient organizations will host and coordinate a medical education program led by a distinguished Visiting Professor with expertise matched to specific unmet educational needs surrounding shared decision making (SDM) and emerging therapeutic options in hemophilia.<sup>1,2</sup>

#### About Hemostasis & Thrombosis Research Society

The Hemostasis and Thrombosis Research Society, Inc. (HTRS) is the leading North American professional society dedicated to research, mentoring, workforce development, and continuing medical education for physicians, investigators, and all health care professionals interested in advancing care for people with hemostatic and thrombotic disorders.

#### **About Pfizer**

Pfizer supports the global healthcare community's independent education initiatives to improve patient outcomes in areas of unmet medical need that are aligned with medical and/or scientific strategies.

## **Eligibility**

### Geographic Scope

United States

### Applicant Eligibility Criteria

- The following may apply: professional medical, nursing, allied health, dental, or pharmacy schools; universities and academic healthcare institutions (both large and small); nonprofit professional organizations or medical societies
- Only organizations are eligible to receive grants (individuals or independent groups of physicians not affiliated with a hospital, academic institution, or professional society are not eligible)
- If the project involves multiple departments within a single institution or is between different institutions, organizations, or associations, each institution, including the requesting organization, must play a defined and relevant role in the project
- The applicant organization must identify an individual to serve as the Project or Program Lead (e.g., the grant coordinator from the applicant organization)
- The Project or Program Lead must be an employee or contractor of the requesting organization
- For projects offering continuing education credit, the requesting organization must supply proof of accreditation

## **Requirements**

## Primary Area of Interest

Hemophilia

## Specific Area of Interest for this RFP

- The intent of this Request for Proposals (RFP) is to invite healthcare institutions with identified needs for hemophilia-focused education to submit applications to host up to a 2-day medical education program at their organization. The program will be led by one Visiting Professor, identified by HTRS, with expertise matched to the organization's unmet educational needs surrounding SDM and emerging therapeutic options in hemophilia care<sup>1,2</sup>
- Organizations interested in applying for a Visiting Professorship must complete the required online application form, including:
  - A description of the Organization's medical gaps, unmet needs, challenges, and questions surrounding SDM and emerging therapeutic options for hemophilia care, for which a Visiting Professorship program could provide significant educational impact.
  - The proposed agenda for a Visiting Professorship Program up to two-days in length.
  - Expected or desired outcomes, including an outline of 6-month outcome metrics describing enduring changes or improvements in patient care and physician education/knowledge made as a result of the Visiting Professorship Program.
  - Proposed Budget of Logistics Expenses.
  - Proof of Accreditation (if applicable).





### **Target Audience**

• Academic clinicians, physician-scientists, and multidisciplinary care teams (MDTs)

### Expected Approximate Monetary Range of Grant Applications

- Individual grant amounts will be up to **\$7,500 USD** to cover local costs (e.g., meeting room rental, AV support, local onsite management, onsite logistics, or planning and staffing needs)
- Please note: HTRS will select one Visiting Professor based on the recipient's approved program and knowledge gaps. **Travel expenses and honoraria for the Visiting Professor will be covered separately and should not be a part of your grant application budget.**
- Approximately eight (8) sites will be supported by this educational program

#### **Key Dates**

- RFP release date: September 17, 2025
- Applications will be accepted on or before 5:00 PM ET on October 28, 2025, and will be reviewed per the timeline below:

Deadline for Applications	Decision Notification Date	Program Start Date must be after
October 28, 2025 at 5:00 PM ET	November 21, 2025	January 2, 2026

IMPORTANT: Applications submitted after 5:00 PM ET on October 28, 2025, will not be reviewed.

#### Components of a Completed Proposal:

- Completed Application Form (<u>Download Here</u>)
- Project Plan/Proposal or Meeting Agenda
- Letter of Support from the Organization
- Proposed Budget of Logistic Expenses
- Proof of Accreditation (if applicable)

#### How to Submit

Applicants are advised to read this section carefully. Submitted applications that do <u>not</u> follow these instructions will not be accepted.

- Go to www.cybergrants.com/pfizer/knowledge and sign in
  - Note: there are individual portals for each grant application type. Please be sure to use the URL above
  - First-time users should click "Create your password"
- Click the "Start A New Knowledge Gap Application" button
- Requirements for submission:
  - Complete all required sections of the online application





- Upload Application Template (<u>Download Here</u>) in the General RFP Submission field
- In the application:
  - For the question "Competitive Grant?" select "Yes"
  - Select the following Primary Area of Interest: **Genetics Hemophilia**
  - Select the following Competitive Grant Program Name: 2025 RD US HTRS Hemophilia Visiting Professorship IME

#### Questions

- If you encounter technical difficulties with the grant application website, please click <a href="here">here</a> or the "Technical Questions" link at the bottom of the page in the grant system
  - If you have questions regarding this RFP, please direct them in writing to Talita Honorato-Rzeszewicz at Pfizer (<a href="mailto:talita.honorato-rzeszewicz@pfizer.com">talita.honorato-rzeszewicz@pfizer.com</a>) or Danielle Horwitz at HTRS (<a href="mailto:dhorwitz@htrs.org">dhorwitz@htrs.org</a>), with the subject line "Visiting Professorship RFP".

### **Review and Approval Process**

 Applications will be considered by an Expert Review Panel (ERP) empowered by Pfizer and HTRS to make final grant decisions. The Review Panel comprises professionals from the medical community identified by HTRS. Pfizer will also have a medical colleague on the Review Panel.

### Mechanism by which Applicants will be Notified

- All applicants will be notified via email on or before November 21, 2025.
- Applicants may be asked for additional clarification during the review period.

## **Grant Agreements**

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click <a href="here">here</a> to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Recipients are encouraged to share the core terms of the agreement with their legal counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the recipient organization.

#### References

- 1. Valentino, L. et al. Personalising haemophilia management with shared decision making. J Haem Pract 8(1), 2021.
- 2. Thornburg C., Coffin D. How clinicians and persons with hemophilia may approach shared decision-making. Exp. Rev. Hem. Vol 17 (6), 2024.



